Cargando…

Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis

Identification of prognostic and predictive biomarkers in idiopathic pulmonary fibrosis (IPF) could aid assessment of disease severity and prediction of progression and response to treatment. This analysis examined reference ranges for neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Nathan, Steven D., Mehta, Jayesh, Stauffer, John, Morgenthien, Elizabeth, Yang, Ming, Limb, Susan L., Bhorade, Sangeeta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037167/
https://www.ncbi.nlm.nih.gov/pubmed/33916077
http://dx.doi.org/10.3390/jcm10071427
_version_ 1783677080296226816
author Nathan, Steven D.
Mehta, Jayesh
Stauffer, John
Morgenthien, Elizabeth
Yang, Ming
Limb, Susan L.
Bhorade, Sangeeta
author_facet Nathan, Steven D.
Mehta, Jayesh
Stauffer, John
Morgenthien, Elizabeth
Yang, Ming
Limb, Susan L.
Bhorade, Sangeeta
author_sort Nathan, Steven D.
collection PubMed
description Identification of prognostic and predictive biomarkers in idiopathic pulmonary fibrosis (IPF) could aid assessment of disease severity and prediction of progression and response to treatment. This analysis examined reference ranges for neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) in IPF, and the relationship between NLR or PLR changes and clinical outcomes over 12 months. This post hoc analysis included patients with IPF from the Phase III, double-blind trials of pirfenidone, ASCEND (NCT01366209) and CAPACITY (NCT00287716 and NCT00287729). The relationship between change from baseline to Month 12 in NLR or PLR (divided into quartiles (Q1–Q4)) and outcomes (mortality, respiratory hospitalization, declines in lung function, exercise capacity and quality of life) was assessed. Estimated reference ranges at baseline for all patients analyzed (n = 1334) were 1.1–6.4 for NLR and 56.8–250.5 for PLR. Significant trends were observed across NLR and PLR quartiles for all outcomes in placebo-treated patients, with patients manifesting the greatest NLR or PLR changes experiencing the worst outcomes. These results suggest that the greatest NLR or PLR changes over 12 months were associated with worse clinical outcomes. Further research is needed to determine the utility of NLR and PLR as prognostic biomarkers in IPF.
format Online
Article
Text
id pubmed-8037167
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80371672021-04-12 Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis Nathan, Steven D. Mehta, Jayesh Stauffer, John Morgenthien, Elizabeth Yang, Ming Limb, Susan L. Bhorade, Sangeeta J Clin Med Article Identification of prognostic and predictive biomarkers in idiopathic pulmonary fibrosis (IPF) could aid assessment of disease severity and prediction of progression and response to treatment. This analysis examined reference ranges for neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) in IPF, and the relationship between NLR or PLR changes and clinical outcomes over 12 months. This post hoc analysis included patients with IPF from the Phase III, double-blind trials of pirfenidone, ASCEND (NCT01366209) and CAPACITY (NCT00287716 and NCT00287729). The relationship between change from baseline to Month 12 in NLR or PLR (divided into quartiles (Q1–Q4)) and outcomes (mortality, respiratory hospitalization, declines in lung function, exercise capacity and quality of life) was assessed. Estimated reference ranges at baseline for all patients analyzed (n = 1334) were 1.1–6.4 for NLR and 56.8–250.5 for PLR. Significant trends were observed across NLR and PLR quartiles for all outcomes in placebo-treated patients, with patients manifesting the greatest NLR or PLR changes experiencing the worst outcomes. These results suggest that the greatest NLR or PLR changes over 12 months were associated with worse clinical outcomes. Further research is needed to determine the utility of NLR and PLR as prognostic biomarkers in IPF. MDPI 2021-04-01 /pmc/articles/PMC8037167/ /pubmed/33916077 http://dx.doi.org/10.3390/jcm10071427 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nathan, Steven D.
Mehta, Jayesh
Stauffer, John
Morgenthien, Elizabeth
Yang, Ming
Limb, Susan L.
Bhorade, Sangeeta
Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis
title Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis
title_full Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis
title_fullStr Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis
title_full_unstemmed Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis
title_short Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis
title_sort changes in neutrophil–lymphocyte or platelet–lymphocyte ratios and their associations with clinical outcomes in idiopathic pulmonary fibrosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037167/
https://www.ncbi.nlm.nih.gov/pubmed/33916077
http://dx.doi.org/10.3390/jcm10071427
work_keys_str_mv AT nathanstevend changesinneutrophillymphocyteorplateletlymphocyteratiosandtheirassociationswithclinicaloutcomesinidiopathicpulmonaryfibrosis
AT mehtajayesh changesinneutrophillymphocyteorplateletlymphocyteratiosandtheirassociationswithclinicaloutcomesinidiopathicpulmonaryfibrosis
AT staufferjohn changesinneutrophillymphocyteorplateletlymphocyteratiosandtheirassociationswithclinicaloutcomesinidiopathicpulmonaryfibrosis
AT morgenthienelizabeth changesinneutrophillymphocyteorplateletlymphocyteratiosandtheirassociationswithclinicaloutcomesinidiopathicpulmonaryfibrosis
AT yangming changesinneutrophillymphocyteorplateletlymphocyteratiosandtheirassociationswithclinicaloutcomesinidiopathicpulmonaryfibrosis
AT limbsusanl changesinneutrophillymphocyteorplateletlymphocyteratiosandtheirassociationswithclinicaloutcomesinidiopathicpulmonaryfibrosis
AT bhoradesangeeta changesinneutrophillymphocyteorplateletlymphocyteratiosandtheirassociationswithclinicaloutcomesinidiopathicpulmonaryfibrosis